Compare · Head-to-head
CJC-1295 vs Liraglutide.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Liraglutide, then use the table to confirm fit.
Liraglutide is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01 · At a glance
| Decision factor | CJC-1295 | Liraglutide |
|---|---|---|
| Primary fit | muscle growth & strength and fat loss & metabolism comparisons | fat loss & metabolism research where you want a clear starting point |
| Evidence | Tier B | Tier A |
| Risk | high | medium |
| Experience level | intermediate | intermediate |
| Budget tier | mid | premium |
| Administration route | subcutaneous | subcutaneous |
02 · Use case & timing
| Decision factor | CJC-1295 | Liraglutide |
|---|---|---|
| Goal fit | Muscle Growth & Strength, Fat Loss & Metabolism, GH Axis Optimization | Fat Loss & Metabolism |
| What users compare it for | Sustained GH and IGF-1 elevation; body composition modulation (long-horizon, not well-established for consumer outcomes). | Moderate weight loss, improved satiety, and HbA1c reduction in clinical populations. |
| Onset timeline | Biomarker effects persist multiple days; IGF-1 elevations up to ~2 weeks after single dose. | Metabolic and appetite effects begin within days to weeks; body-weight effects build over months. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | CJC-1295 | Liraglutide |
|---|---|---|
| Adverse effects | Injection-site reactions, headache, diarrhea, flushing, transient hypotension at higher doses. | GI effects are common, especially nausea, vomiting, constipation, and diarrhea. Pancreatitis and gallbladder events remain class concerns. |
| Contraindications | GH-axis stimulation risks: glucose intolerance, theoretical neoplasia concerns with elevated IGF-1. | Avoid in personal or family history of medullary thyroid carcinoma or MEN2. Use caution with pancreatitis history and pregnancy. |
| Interaction notes | Monitor insulin/glucose sensitivity, thyroid axis, and cortisol/prolactin. Trials report no significant cortisol/prolactin/TSH/LH increases at 60 µg/kg single dose. | Same class cautions as other GLP-1 agents: hypoglycemia risk rises with insulin or sulfonylureas, and gastric emptying delay can affect oral medications. |
| Regulatory status | Not approved | Prescription-approved |
| FDA flag | FDA compounding caution | FDA status unclear |
| WADA status | WADA S2 | Not listed |
04 · Age & monitoring
| Decision factor | CJC-1295 | Liraglutide |
|---|---|---|
| Supported age ranges | 25-34, 35-44, 45-54 | 25-34, 35-44, 45-54, 55-64, 65+ |
| Life-stage note | Midlife is where GH-restoration framing is most often used, but evidence and long-term safety remain limited. | Adult metabolic-health use case with the strongest fit when evidence and regulatory clarity matter more than novelty. |
| Monitoring burden | high | medium |
| Follow-up cadence | Reassess at startup and then roughly every few months if continuing. | Early review in the first month, then periodic follow-up every few months. |
05 · Cost & sourcing
| Decision factor | CJC-1295 | Liraglutide |
|---|---|---|
| Typical cycle cost | $143.98 | No reliable estimate yet |
| Estimated monthly cost | $47.99 | No reliable estimate yet |
| Cost confidence | High confidence | No estimate |
06 · Before you buy
| Decision factor | CJC-1295 | Liraglutide |
|---|---|---|
| Tracked vendor listings | 3 listings | 0 listings |
| Sourcing note | At least one listing is a blend rather than a clean standalone product, so review the product page carefully. | No tracked product page yet, so sourcing takes more manual review. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.